Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18802544 | MOLECULAR MARKER SIGNIFICANTLY ASSOCIATED WITH VITAMIN E CONTENT IN SOYBEANS, KOMPETITIVE ALLELE SPECIFIC POLYMERASE CHAIN REACTION PRIMERS COMBINATION AND APPLICATION THEREOF | August 2024 | December 2024 | Allow | 5 | 0 | 0 | Yes | No |
| 18430156 | METHODS AND COMPOSITIONS FOR DETECTING ESOPHAGEAL NEOPLASIAS AND/OR METAPLASIAS IN THE ESOPHAGUS | February 2024 | October 2024 | Allow | 8 | 1 | 0 | Yes | No |
| 18393314 | METHOD FOR ISOLATING TARGET NUCLEIC ACID USING HETERODUPLEX BINDING PROTEINS | December 2023 | February 2026 | Abandon | 26 | 1 | 0 | No | No |
| 18262812 | P27 SINGLE-NUCLEOTIDE POLYMORPHISM T2871099G AS A PREDICTOR OF THE BENEFIT OF ENDOCRINE THERAPY ALONE OR IN COMBINATION WITH CDK INHIBITORS IN BREAST CANCER | July 2023 | March 2026 | Allow | 32 | 0 | 1 | Yes | No |
| 18037361 | SENSITIVE QUANTITATIVE DETECTION OF SARS-CoV-2 USING DIGITAL WARM-START CRISPR ASSAY | May 2023 | October 2025 | Allow | 29 | 1 | 0 | Yes | No |
| 18092558 | HPV E6, E7 MRNA Assay and Methods of Use Thereof | January 2023 | September 2025 | Abandon | 33 | 0 | 1 | No | No |
| 17990445 | DNAZYME-BASED SENSOR FOR STAPHYLOCOCCUS AUREUS | November 2022 | February 2026 | Allow | 39 | 1 | 1 | Yes | No |
| 17919293 | METHOD OF DETERMINING THE PHENOTYPE OF A HAIR FOLLICLE | October 2022 | January 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17906032 | COMPOSITIONS AND METHODS FOR THE SELECTIVE DETECTION OF TUMOR-DERIVED VIRAL DNA | September 2022 | November 2025 | Allow | 38 | 0 | 1 | Yes | No |
| 17904910 | METHODS FOR DIAGNOSING, PROGNOSING AND MANAGING TREATMENT OF BREAST CANCER | August 2022 | January 2026 | Allow | 41 | 1 | 0 | No | No |
| 17760308 | LOOP-MEDIATED ISOTHERMAL AMPLIFICATION PRIMERS FOR VIBRIO PARAHAEMOLYTICUS DETECTION AND USES THEREOF | August 2022 | October 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17815082 | METHOD FOR DETERMINING PRESENCE OR ABSENCE OF RISK OF DEVELOPING CANCER | July 2022 | September 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17865590 | METHOD FOR PRODUCING PLURIPOTENT STEM CELL CAPABLE OF DIFFERENTIATING INTO SPECIFIC CELL AND APPLICATION THEREOF | July 2022 | January 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17793164 | METHODS OF CAPTURING, SEPARATING, AND/OR ENRICHING LOW ABUNDANT TARGET BIOMOLECULES | July 2022 | February 2026 | Abandon | 43 | 1 | 0 | No | No |
| 17812496 | PRIMER AND PROBE SETS FOR PATHOGEN DETECTION OF INFECTION IN TRANSPLANT PATIENT, KIT AND USE THEREOF | July 2022 | August 2025 | Allow | 37 | 1 | 0 | No | No |
| 17863293 | DETECTION METHOD USING PAPER CHIP CAPABLE OF MULTI-NUCLEIC ACID COLORIMETRIC DETECTION WITH ONE-STEP | July 2022 | January 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17855742 | METHODS FOR ASSESSING THE PRESENCE OR ABSENCE OF REPLICATION COMPETENT VIRUS | June 2022 | November 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17843717 | PRIMER SET FOR DETECTING MYCOBACTERIUM TUBERCULOSIS, MYCOBACTERIUM AVIUM, AND MYCOBACTERIUM INTRACELLULARE AND METHOD USING SAME, AND REAGENT KIT THEREFOR | June 2022 | February 2026 | Abandon | 44 | 1 | 0 | No | No |
| 17776315 | PRIMER, PROBE AND KIT FOR TUBERCULOSIS DIAGNOSIS USING URINE SAMPLE, AND USES THEREOF | May 2022 | January 2026 | Abandon | 44 | 1 | 0 | No | No |
| 17727394 | CANCER THERAPEUTIC METHODS | April 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17710204 | COMPOSITIONS AND METHODS OF USING HisGTG TRANSFER RNAS (tRNAs) | March 2022 | February 2025 | Abandon | 35 | 3 | 1 | No | No |
| 17754091 | Detection of Mycobacterium species | March 2022 | December 2025 | Allow | 45 | 2 | 0 | Yes | No |
| 17692698 | Method for Predicting Effectiveness of Angiogenesis Inhibitor | March 2022 | May 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17671951 | MAJOR HISTOCOMPATIBILITY COMPLEX SINGLE NUCLEOTIDE POLYMORPHISMS | February 2022 | June 2025 | Allow | 40 | 0 | 1 | Yes | No |
| 17668553 | Non-Invasive Assays for Embryo Quality | February 2022 | April 2025 | Allow | 38 | 1 | 1 | No | No |
| 17581371 | Biomarkers for Autism Spectrum Disorders | January 2022 | July 2025 | Allow | 42 | 2 | 1 | Yes | No |
| 17566566 | ANTI-POLLUTION CONSUMABLE AND METHOD FOR CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS (CRISPR) MOLECULAR DIAGNOSIS USING SAME | December 2021 | December 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17549345 | Systems and Methods using Nucleic Acid Photoacoustic Nanosensors for Cytokine Detection | December 2021 | December 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17613737 | METHODS FOR DETECTING A LEVEL OF H. PYLORI IN A FECAL SAMPLE | November 2021 | February 2026 | Abandon | 51 | 1 | 1 | No | No |
| 17600371 | Intestinal Biomarkers For Gut Health In Domesticated Birds | September 2021 | January 2026 | Abandon | 52 | 1 | 1 | No | No |
| 17476902 | METHODS OF IDENTIFYING SNPS CORRELATING WITH ELITE ATHLETIC PERFORMANCE | September 2021 | December 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17472740 | Methods for Detecting an increased risk for coronary heart disease | September 2021 | October 2024 | Allow | 37 | 2 | 1 | No | No |
| 17377231 | NOVEL ALK AND NTRK1 FUSION MOLECULES AND USES THEREOF | July 2021 | September 2025 | Allow | 50 | 1 | 1 | Yes | No |
| 17355932 | METHOD OF TESTING FOR SPECIFIC ORGANISMS IN AN INDIVIDUAL | June 2021 | June 2025 | Abandon | 48 | 6 | 1 | Yes | No |
| 17354899 | NON-INVASIVE SKIN-BASED DETECTION METHODS | June 2021 | February 2025 | Abandon | 44 | 3 | 0 | No | No |
| 17354894 | NON-INVASIVE SKIN-BASED DETECTION METHODS | June 2021 | February 2026 | Abandon | 56 | 5 | 0 | No | No |
| 17331460 | PROCESS FOR IDENTIFYING AND QUANTIFYING NUCLEIC ACID SEQUENCES FROM LIVE MICROORGANISMS | May 2021 | December 2024 | Abandon | 43 | 2 | 0 | Yes | No |
| 17200302 | MULTIPLEXED ASSAY FOR QUANTITATING AND ASSESSING INTEGRITY OF CELL-FREE DNA IN BIOLOGICAL FLUIDS FOR CANCER DIAGNOSIS, PROGNOSIS AND SURVEILLANCE | March 2021 | February 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17137191 | DNA BARCODE FOR VARIETY IDENTIFICATION OF WOLFBERRY AND IDENTIFICATION METHOD THEREFOR | December 2020 | January 2025 | Allow | 48 | 2 | 2 | Yes | No |
| 17254304 | MOLECULAR MARKER COMBINATION LINKED TO QUANTITATIVE TRAITS OF TEA PLANT CAFFEINE CONTENT | December 2020 | June 2025 | Allow | 54 | 2 | 1 | No | No |
| 16973317 | METHODS AND TOOLS FOR PLANT PATHOGEN ASSESSMENT | December 2020 | April 2025 | Allow | 52 | 2 | 1 | No | No |
| 17078036 | LYSINIBACILLUS SPHAERICUS AND ASPIRIN CHEMOPREVENTION OF COLORECTAL CANCER | October 2020 | December 2024 | Allow | 50 | 4 | 1 | Yes | No |
| 16978088 | IDENTIFICATION METHOD FOR DERMAL SHEATH CUP CELLS (DSCC), AND METHOD FOR EVALUATING COMPOSITION FOR HAIR FOLLICLE REGENERATION | September 2020 | January 2025 | Abandon | 53 | 2 | 0 | No | No |
| 16767509 | GENETIC BIOMARKER PROFILES FOR ENDURANCE SPORT SUITABILITY | May 2020 | December 2024 | Abandon | 55 | 3 | 1 | No | No |
| 16756625 | CELL ATLAS OF HEALTHY AND DISEASED TISSUES | April 2020 | March 2026 | Abandon | 60 | 6 | 2 | No | No |
| 16630523 | DETECTING TISSUE-SPECIFIC DNA | January 2020 | December 2023 | Abandon | 47 | 5 | 1 | No | No |
| 16603435 | NON-INVASIVE SKIN-BASED DETECTION METHODS | October 2019 | January 2026 | Abandon | 60 | 7 | 1 | No | No |
| 16479427 | A METHOD OF TARGETING PATIENT-SPECIFIC ONCOGENES IN EXTRACHROMOSOMAL DNA TO TREAT GLIOBLASTOMA | July 2019 | October 2025 | Allow | 60 | 6 | 1 | No | No |
| 16371984 | ANALYSIS OF ACELLULAR NUCLEIC ACIDS | April 2019 | September 2025 | Abandon | 60 | 8 | 0 | Yes | No |
| 16315405 | METHODS AND COMPOSITIONS FOR DETECTING ESOPHAGEAL NEOPLASIAS AND/OR METAPLASIAS IN THE ESOPHAGUS | January 2019 | November 2024 | Allow | 60 | 7 | 1 | Yes | Yes |
| 16305071 | METHOD FOR RNA TAGGING AND ANALYSIS ON SINGLE CELL | November 2018 | July 2025 | Abandon | 60 | 6 | 0 | No | Yes |
| 16081069 | ANALYZING RNA FOR DIAGNOSING INFECTION TYPE | August 2018 | February 2022 | Allow | 42 | 5 | 2 | Yes | No |
| 15879921 | COMPOSITIONS AND METHODS FOR DETECTING HEPATITIS B VIRUS | January 2018 | April 2020 | Allow | 27 | 2 | 0 | No | No |
| 15305598 | METHOD FOR DIAGNOSING HEPATIC FIBROSIS | October 2016 | February 2019 | Allow | 28 | 1 | 1 | Yes | No |
| 14727536 | METHOD AND PROBE SET FOR DETECTING CANCER | June 2015 | May 2017 | Allow | 23 | 2 | 0 | Yes | No |
| 14331417 | METHOD AND PROBE SET FOR DETECTING CANCER | July 2014 | January 2015 | Allow | 6 | 0 | 0 | Yes | No |
| 14357373 | METHOD FOR PREDICTING RISK OF PORENCEPHALY OR CEREBRAL HEMORRHAGE | May 2014 | November 2016 | Allow | 30 | 1 | 0 | Yes | No |
| 13965083 | Detection and Treatment of Polycystic Kidney Disease | August 2013 | February 2017 | Allow | 42 | 2 | 1 | Yes | No |
| 13925443 | LaFORA'S DISEASE GENE | June 2013 | January 2016 | Allow | 30 | 4 | 0 | Yes | No |
| 13911733 | COMPOSITIONS FOR DETECTING ALICYCLOBACILLUS MICROORGANISMS | June 2013 | February 2016 | Allow | 32 | 1 | 1 | No | No |
| 13893067 | METHOD AND PROBE SET FOR DETECTING CANCER | May 2013 | March 2014 | Allow | 10 | 1 | 0 | No | No |
| 13639756 | CIRCULATING BIOMARKERS FOR METASTATIC PROSTATE CANCER | April 2013 | May 2016 | Allow | 44 | 2 | 1 | Yes | No |
| 13696937 | METHOD AND KIT FOR DISCRIMINATING BETWEEN BREAST CANCER AND BENIGN BREAST DISEASE | November 2012 | December 2015 | Allow | 37 | 3 | 1 | Yes | No |
| 13584369 | METHOD OF PROFILING GENE EXPRESSION IN A SUBJECT HAVING COLORECTAL CANCER | August 2012 | October 2013 | Allow | 14 | 1 | 0 | No | No |
| 13260508 | METHOD FOR DETERMINING THE PREDISPOSITION OF A PATIENT TO CHANGED BIOTRANSFORMATION AND TO THE DEVELOPMENT OF UNDESIRED DRUG EFFECTS IN A TREATMENT OF THE PATIENT WITH ATROVASTATIN | December 2011 | August 2016 | Allow | 59 | 5 | 1 | Yes | No |
| 13114801 | Method and Kit for Diagnosing Autism Using Gene Expression Profiling | May 2011 | December 2014 | Allow | 43 | 3 | 1 | Yes | No |
| 13091702 | SORTING SYSTEM FOR CATTLE | April 2011 | June 2013 | Allow | 26 | 0 | 0 | Yes | No |
| 13023295 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF | February 2011 | March 2012 | Allow | 13 | 0 | 1 | Yes | No |
| 12777042 | KITS AND PRIMERS FOR DIAGNOSING SCHIZOPHRENIA | May 2010 | June 2012 | Allow | 25 | 1 | 0 | Yes | No |
| 12769896 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF | April 2010 | February 2012 | Allow | 22 | 0 | 1 | Yes | No |
| 12764841 | MUTATIONS ASSOCIATED WITH LONG QT SYNDROME | April 2010 | October 2013 | Allow | 42 | 1 | 1 | Yes | No |
| 12757918 | METHOD OF PROFILING GENE EXPRESSION IN A HEALTHY SUBJECT | April 2010 | September 2011 | Allow | 17 | 1 | 0 | No | No |
| 12757930 | METHOD OF PROFILING GENE EXPRESSION IN A SUBJECT HAVING HEART FAILURE | April 2010 | January 2012 | Allow | 21 | 2 | 0 | No | No |
| 12757921 | METHOD OF PROFILING GENE EXPRESSION IN A SUBJECT UNDERGOING A TREATMENT | April 2010 | October 2011 | Allow | 18 | 1 | 0 | No | No |
| 12757934 | METHOD OF PROFILING GENE EXPRESSION IN A SUBJECT HAVING AN INFECTIOUS DISEASE | April 2010 | December 2011 | Allow | 20 | 1 | 0 | No | No |
| 12757925 | METHOD OF PROFILING GENE EXPRESSION IN A SUBJECT HAVING ALZHEIMER'S DISEASE | April 2010 | May 2012 | Allow | 25 | 2 | 0 | No | Yes |
| 12757928 | METHOD OF PROFILING GENE EXPRESSION IN A SUBJECT HAVING DIABETES | April 2010 | December 2011 | Allow | 20 | 1 | 0 | No | No |
| 12757931 | METHOD OF PROFILING GENE EXPRESSION IN A SUBJECT HAVING PROSTATE CANCER | April 2010 | November 2011 | Allow | 19 | 1 | 0 | No | No |
| 12757914 | METHOD OF PROFILING GENE EXPRESSION IN A SUBJECT HAVING DISEASE | April 2010 | October 2011 | Allow | 18 | 1 | 0 | No | No |
| 12667273 | UNIQUE CALIBRATOR POLYNUCLEOTIDES AND METHODS OF USING IN QUANTITATIVE NUCLEIC ACID ASSAYS | December 2009 | September 2013 | Allow | 45 | 4 | 1 | No | No |
| 12642028 | Screening for Arthrogryposis Multiplex in Bovines | December 2009 | December 2012 | Allow | 36 | 2 | 1 | Yes | No |
| 12636082 | GENETIC VARIANTS AS MARKERS FOR USE IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF EOSINOPHILIA, ASTHMA, AND MYOCARDIAL INFARCTION | December 2009 | November 2012 | Allow | 35 | 1 | 1 | No | No |
| 11813450 | METHOD OF JUDGING INFLAMMATORY DISEASE BY USING SINGLE NUCLEOTIDE POLYMORPHISM | October 2009 | April 2013 | Allow | 60 | 3 | 1 | Yes | No |
| 12310826 | GENOMIC MARKER FOR TENDERNESS MEAT | June 2009 | October 2011 | Allow | 31 | 0 | 1 | No | No |
| 12279178 | TREATMENT RESPONSE IN GENERALIZED SOCIAL PHOBIA | April 2009 | May 2011 | Allow | 33 | 0 | 0 | Yes | No |
| 12420722 | METHODS FOR SCREENING FOR GENETIC PREDISPOSITION TO TYPE I DIABETES | April 2009 | May 2012 | Allow | 37 | 1 | 2 | Yes | No |
| 12302960 | METHOD OF DETERMINING AN AMOUNT OF FATTY ACID CONTENTS IN BOVINE INTRAMUSCULAR FAT ON THE BASIS OF GENOTYPE OF FATTY ACID SYNTHASE GENE AND METHOD OF DETERMINING GOODNESS OF EATING QUALITY OF BEEF ON THE BASIS OF THE RESULTS THEREOF | December 2008 | October 2011 | Allow | 34 | 1 | 1 | Yes | No |
| 12315114 | Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition | November 2008 | November 2013 | Allow | 60 | 5 | 1 | Yes | Yes |
| 12287629 | BIOMARKERS FOR DIAGNOSING SCHIZOPHRENIA AND BIPOLAR DISORDER | October 2008 | December 2009 | Allow | 15 | 0 | 0 | No | No |
| 12184018 | GENETIC VARIATION IN PRO-MELANIN-CONCENTRATING HORMONE GENE AFFECTS CARCASS TRAITS IN CATTLE | July 2008 | April 2011 | Allow | 32 | 2 | 0 | Yes | No |
| 11997678 | NALP7-BASED DIAGNOSIS OF FEMALE REPRODUCTIVE CONDITIONS | February 2008 | March 2011 | Allow | 37 | 2 | 1 | Yes | No |
| 11949604 | METHODS OF PREDICTING RESISTANCE OR SENSITIVITY TO THERAPIES FOR CANCER | December 2007 | January 2013 | Allow | 60 | 3 | 1 | Yes | No |
| 11938684 | NUCLEIC ACID AMPLIFICATION AND DETECTION OF MYCOBACTERIUM SPECIES | November 2007 | October 2010 | Allow | 35 | 1 | 1 | No | No |
| 11979262 | Lafora's disease gene | October 2007 | March 2013 | Allow | 60 | 4 | 0 | Yes | Yes |
| 11975703 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF | October 2007 | November 2010 | Allow | 37 | 1 | 1 | No | No |
| 11901238 | POLYMORPHISMS IN THE HUMAN GENE FOR THE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1 (MRP-1) AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | September 2007 | May 2011 | Allow | 44 | 2 | 1 | Yes | No |
| 11893086 | ROLE OF FGF-20 IN CANCER DIAGNOSIS AND TREATMENT | August 2007 | May 2010 | Allow | 33 | 1 | 2 | No | No |
| 11827992 | GENETIC POLYMORPHISMS ASSOCIATED WITH ALZHEIMER'S DISEASE, METHODS OF DETECTION AND USES THEREOF | July 2007 | August 2009 | Allow | 25 | 1 | 1 | Yes | No |
| 11751845 | METHODS, PANELS OF IDENTIFICATION MARKERS, AND KITS FOR IDENTIFYING FORENSIC SAMPLES | May 2007 | June 2011 | Allow | 49 | 2 | 1 | Yes | No |
| 11751429 | METHOD AND PROBE SET FOR DETECTING CANCER | May 2007 | April 2011 | Allow | 46 | 3 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SWITZER, JULIET CAROLINE.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 12.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SWITZER, JULIET CAROLINE works in Art Unit 1682 and has examined 141 patent applications in our dataset. With an allowance rate of 87.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 40 months.
Examiner SWITZER, JULIET CAROLINE's allowance rate of 87.9% places them in the 68% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by SWITZER, JULIET CAROLINE receive 2.12 office actions before reaching final disposition. This places the examiner in the 57% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SWITZER, JULIET CAROLINE is 40 months. This places the examiner in the 23% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +18.8% benefit to allowance rate for applications examined by SWITZER, JULIET CAROLINE. This interview benefit is in the 61% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 26.2% of applications are subsequently allowed. This success rate is in the 43% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 47.1% of cases where such amendments are filed. This entry rate is in the 71% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 70% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 93.3% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 56.5% are granted (fully or in part). This grant rate is in the 58% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 24.8% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.6% of allowed cases (in the 66% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.